Loss Expected to Narrow for ACADIA Pharmaceuticals (ACAD)

ACADIA Pharmaceuticals  is expected to book a narrower loss than a year ago when it reports second quarter earnings on Tuesday, August 6, 2013 with analysts expecting a loss of nine cents per share, up from a loss of 10 cents per share a year ago.

Analysts are expecting a loss of 36 cents per share for the fiscal year. For the year, revenue is expected to come in at $1.8 million.

Over the last four quarters, the company has seen an average of more than twofold year-over-year growth in revenue. The biggest rise came in the third quarter, with revenue growing more than fivefold from the year-ago quarter.

The majority of analysts (100%) rate ACADIA Pharmaceuticals as a buy. This compares favorably to the analyst ratings of its nearest eight competitors, which average 52% buys. All eight analysts rate ACADIA Pharmaceuticals as a buy.

Competitors in the healthcare sector include: Allergan , Bristol Myers and Johnson & Johnson .

Earnings estimates provided by Zacks.

Narrative Science, through its proprietary artificial intelligence platform, transforms data into stories and insights.